VERU INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
VERU INC. (VERU) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 0 shares for the 3-month period ending 2015-12-31, per its 10-Q filed 2016-02-02.
Discontinued › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2016-02-02
- VERU INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2015-12-31 was 0.00 shares.
- VERU INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2014-12-31 was 0.00 shares.
- VERU INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2014-06-30 was 0.00 shares.
- VERU INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2013-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- VERU INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2013 was 150.00K shares, a 0.00% change from fiscal 2012.
- VERU INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2012 was 150.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month |
|---|---|---|---|---|---|
| 2015-12-31 | 0.00 shares 10-Q · filed 2016-02-02 | ||||
| 2014-12-31 | 0.00 shares 10-Q · filed 2016-02-02 | ||||
| 2014-06-30 | 0.00 shares 10-Q · filed 2014-07-31 | 0.00 shares 10-Q · filed 2014-07-31 | |||
| 2013-12-31 | 0.00 shares 10-Q · filed 2015-02-03 | 150.00K shares derived: sum of 2 quarters · filed 2015-02-03 | 150.00K shares derived: sum of 3 quarters · filed 2015-02-03 | 150.00K shares derived: sum of 4 quarters · filed 2015-02-03 | |
| 2013-09-30 | 150.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-03 | 150.00K shares derived: sum of 2 quarters · filed 2014-07-31 | 150.00K shares derived: sum of 3 quarters · filed 2014-07-31 | 150.00K shares 10-K · filed 2013-12-03 | |
| 2013-06-30 | 0.00 shares 10-Q · filed 2014-07-31 | 0.00 shares derived: sum of 2 quarters · filed 2014-07-31 | 0.00 shares 10-Q · filed 2014-07-31 | 150.00K shares 10-Q · filed 2013-08-01 | 150.00K shares derived: sum of 4 quarters · filed 2014-07-31 |
| 2013-03-31 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2013-05-02 | 150.00K shares 10-Q · filed 2013-05-02 | 150.00K shares derived: sum of 3 quarters · filed 2013-05-02 | ||
| 2012-12-31 | 150.00K shares 10-Q · filed 2013-01-30 | 150.00K shares derived: sum of 2 quarters · filed 2013-01-30 | |||
| 2012-09-30 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2012-12-04 | 150.00K shares 10-K · filed 2012-12-04 | |||
| 2012-06-30 | 150.00K shares 10-Q · filed 2012-07-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |